EMA Accepts Humira and Remicade Biosimilars for Regulatory Review
Humira II-198 - SMOP
Fear not, AbbVie. Sales king Humira might have a graceful fall from biosim attack: analyst | Fierce Pharma
AbbVie drops legal case against EMA - PMLiVE
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma - KED Global
Adalimumab (Humira) - News, Articles etc. - European Pharmaceutical Review
Amgen's two-brand strategy? EU thumbs up for Humira biosimilar duo
Humira, INN-adalimumab
EMA defends Humira redactions, says only commercial info was blacked out
Humira; INN-adalimumab
Pfizer, AbbVie settle Humira biosimilar dispute | Crain's Chicago Business
Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval
Amgevita (adalimumab) Biosimilar | Amgen
EMA Accepts Humira and Remicade Biosimilars for Regulatory Review
Humira, INN-adalimumab
Humira, INN-adalimumab
Approval status of adalimumab biosimilars. | Download Scientific Diagram
Boehringer Biosimilar to Humira Accepted for Regulatory Review - Pharmaceutical Processing World
Characterisation of Humira Adalimumab by high resolution mass spectrometry | Quality Assistance
IBD Biosimilar Imraldi Wins Approval Recommendation by EMA Committee
EMA accepts Sandoz's application for high concentration of biosimilar
Pharmaceutics | Free Full-Text | The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
EMA accepts application for high concentration adalimumab biosimilar
Humira Biosimilar AVT02 Accepted for Regulatory Review in US, Europe
